询价
NanoTemper 官方博客

NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

2 min read
三月 24, 2022
Dianthus Instrument left view image roadblock featured image

SOUTH SAN FRANCISCO, Calif. 三月 24, 2022 — NanoTemper Technologies, announced today the launch of 光谱位移技术 Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery. This breakthrough technology removes the roadblocks experienced by scientists dealing with really complex molecular interactions often seen in challenging drugs and drug targets like Proteolysis-targeting chimeras (PROTACs), Intrinsically Disordered Proteins (IDPs), or fragment libraries.

Scientists feel stuck because traditional screening methods like SPR or ITC haven’t been able to handle these difficult molecular interactions, or at best they offer very low-quality data. So, scientists end up making decisions with a lot of uncertainty since the results don’t clearly point to the best hits. Or, they spend too much time on lengthy assay development to characterize tricky interactions like ternary complexes and binary interactions with covalent ligands.

“Spectral Shift changes that,” comments Amit Gupta, Product Manager at NanoTemper. “Not only does it perform very precise measurements that generate such high-quality data for hit identification or lead optimization, but it requires little to no assay development.” These are huge wins for scientists working with undruggable targets like KRAS or STAT3. Finally experiencing increased success with screening campaigns and feeling confident they’re getting trustworthy results is such a relief.

“At NanoTemper, our vision is to help create a world where every disease is treatable, so it’s important that we create biophysical tools as quickly as possible to help scientists tackle their most challenging characterizations,” says Philipp Baaske, Co-founder and CEO of NanoTemper. “We put it in the hands of important biopharma companies, and early adoption of Spectral Shift in Dianthus was faster than we could have imagined — it validated the impact we believe it will have on the industry.”

Experience Spectral Shift and Dianthus for yourself, visit nanotempertech.com/dianthus.

 

关于 NanoTemper Technologies

NanoTemper Technologies 公司的使命是为科学家创造生物物理学工具,以解决表征中最具挑战性的问题。我们非常兴奋能够同致力于改变世界的药物研发或与基础研究科学家合作。如果您在亲和力筛选、分子相作、蛋白稳定性或蛋白生产等方面遇到挑战,请联系我们。

联系我们
John Valdez, Director of Marketing
john.valdez@nanotempertech.com
415.670.0424